The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently,...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899358/ https://www.ncbi.nlm.nih.gov/pubmed/17593981 |
_version_ | 1782133939612155904 |
---|---|
author | Richardson, H. Johnston, D. Pater, J. Goss, P. |
author_facet | Richardson, H. Johnston, D. Pater, J. Goss, P. |
author_sort | Richardson, H. |
collection | PubMed |
description | Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (ais) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (ncic ctg) has developed a randomized phase iii study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The ncic ctg map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene. |
format | Text |
id | pubmed-1899358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Multimed Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-18993582007-06-26 The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial Richardson, H. Johnston, D. Pater, J. Goss, P. Curr Oncol Canadian Centre Activities Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (ais) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (ncic ctg) has developed a randomized phase iii study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The ncic ctg map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene. Multimed Inc. 2007-06 /pmc/articles/PMC1899358/ /pubmed/17593981 Text en 2007 Multimed Inc. |
spellingShingle | Canadian Centre Activities Richardson, H. Johnston, D. Pater, J. Goss, P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
title | The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
title_full | The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
title_fullStr | The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
title_full_unstemmed | The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
title_short | The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
title_sort | national cancer institute of canada clinical trials group map.3 trial: an international breast cancer prevention trial |
topic | Canadian Centre Activities |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899358/ https://www.ncbi.nlm.nih.gov/pubmed/17593981 |
work_keys_str_mv | AT richardsonh thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT johnstond thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT paterj thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT gossp thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT richardsonh nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT johnstond nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT paterj nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial AT gossp nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial |